Denali regains full rights to DNL593 as Takeda terminates collaboration agreement

Filed April 3, 2026 · Period ending April 3, 2026 · ~1 min read

Key Changes

• high

  Takeda terminated the 2018 collaboration agreement for DNL593, effective 60 days from April 3, 2026. All development and commercialization rights revert to Denali with no further financial obligations.

  Item 1.02 verify on EDGAR →
• medium

  Takeda cited strategic considerations for the termination, explicitly stating the decision was not related to efficacy or safety data from the DNL593 program.

  Item 1.02 verify on EDGAR →
• high

  Denali now has full control over DNL593's future development strategy and potential commercialization without partnership constraints or revenue-sharing obligations.

  Item 1.02 verify on EDGAR →